Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to VRd. The 6...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Cancer J
Auteurs principaux: Durie, Brian G. M., Hoering, Antje, Sexton, Rachael, Abidi, Muneer H., Epstein, Joshua, Rajkumar, S. Vincent, Dispenzieri, Angela, Kahanic, Stephen P., Thakuri, Mohan C., Reu, Frederic J., Reynolds, Christopher M., Orlowski, Robert Z., Barlogie, Bart
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214419/
https://ncbi.nlm.nih.gov/pubmed/32393732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0311-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires